Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate

Lara C. Pullen, PhD  |  January 30, 2017

A recent analysis has examined the effectiveness of baricitinib in treating RA patients who suffer from comorbidities and the effect of concomitant use of steroids. Baricitinib proved effective, particularly in patients who had exposure to cDMARDs and corticosteroids…

Full Circle: How Becoming an Educator Reenergized a Rheumatologist’s Career

Karen Appold  |  January 27, 2017

Career changes can be difficult. But for Stanford Shoor, MD, leaving clinical practice and becoming an educator in the field of rheumatology has been “a renaissance.”

FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2017

FDA Review of Baricitinib Delayed The U.S. Food and Drug Administration (FDA) has extended the review period for baricitinib, an investigational medication for treating moderate to severe rheumatoid arthritis (RA).1 Baricitinib is a once-daily oral Janus kinase (JAK) inhibitor currently in clinical studies for inflammatory and autoimmune diseases. The New Drug Application (NDA) for baricitinib…

Rheumatology Coding Corner Answer: Coding for a Knee Injection

From the College  |  January 25, 2017

CPT: 20611-LT, J7325 X 1 ICD-9: 715.16—Osteoarthritis, localized, primary, lower leg ICD-10: M17.12—Unilateral primary osteoarthritis, left knee Note: When billing for 20611—Arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee, subacromial bursa), with permanent recording and reporting, there must be a permanent photograph of the needle placement in the patient’s medical chart….

Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2017

EULAR has updated its recommendations for the management of early arthritis, outlining aspects of diagnosis and drug treatments…

Distinct Autoantigens Found in Patients with Scleroderma & Coincident Cancer

Lara C. Pullen, PhD  |  January 24, 2017

Recent research examined the relationship between patients with scleroderma who are anti-CTP antibody negative and cancer. Combing two complementary technologies, PhIP-Seq and PLATO-BC, researchers identified the POLR3 complex in cancer-associated scleroderma…

Sen. Susan Collins: Trump’s Obamacare Order ‘Confusing;’ Replacement Law Needed

Susan Cornwell  |  January 23, 2017

WASHINGTON (Reuters)—U.S. Sen. Susan Collins (R-Me.) called President Donald Trump’s executive order against Obamacare “very confusing” on Monday, saying whatever actions the Trump administration takes, legislation will still be needed to replace the health insurance law. “We really don’t know yet what the impact (of the order) will be,” Collins told reporters, adding that it…

Trump May Not Enforce Individual Health Insurance Mandate

Reuters Staff  |  January 23, 2017

WASHINGTON (Reuters)—The Trump administration may no longer enforce a rule requiring individual Americans to carry health insurance or pay a penalty if they do not, a senior White House official said on Sunday Speaking on ABC’s “This Week” program, Kellyanne Conway, counselor to the president, said President Donald Trump “may stop enforcing the individual mandate.”…

Siting Your Rural Rheumatology Practice & Other Rural Rheum Concerns

Richard Quinn  |  January 20, 2017

Do you want to practice near a highway off-ramp or a supermarket? Where a rural rheumatology practice is located may be the key to success…

Why Keep a Seat at the AMA Table?

Kelly Tyrrell  |  January 18, 2017

As 2017 unfolds—a year when MACRA begins, lawmakers take steps to dismantle the health reform efforts of the past eight years, and political uncertainty is the rule—it is imperative that the ACR leverage its advocacy agenda by maintaining its seat at the American Medical Association’s (AMA’s) House of Delegates (HOD), says Gary Bryant, MD, FACP…

  • « Previous Page
  • 1
  • …
  • 221
  • 222
  • 223
  • 224
  • 225
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences